ALDH1A1 and ovarian carcinoma: Also worthy of further clinical exploration are expression levels of CD44, ALDH1, p-FAK/FAK, and p-YB1/YB1, as well as CSCs and other potential predictors and/or pharmacodynamic biomarkers, in ovarian cancer.